1. 1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes. (26th November 2018) Authors: Ford, Christopher; Henn, Matthew; Bryant, Jessica; Diao, Liyang; Wortman, Jennifer; Tomlinson, Amelia; Litcofsky, Kevin; Bernardo, Patricia; McGovern, Barbara; Aunins, John G; Cook, David N; Trucksis, Michele Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner. (26th November 2018) Authors: Henn, Matthew; Ford, Christopher; O'Brien, Edward; Wortman, Jennifer; Diao, Liyang; Desjardins, Christopher; Tomlinson, Amelia; Litcofsky, Kevin; Wilcox, Mark; Buckley, Anthony; Bernardo, Patricia; McGovern, Barbara; Aunins, John G; Cook, David N; Trucksis, Michele Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI). (4th October 2017) Authors: Henn, Matthew; Ford, Christopher; O'Brien, Edward; Wortman, Jennifer; Simmons, Sheri; Diao, Liyang; Litcofsky, Kevin; Bernardo, Patricia; Aunins, John; Cook, David; Trucksis, Michele Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗